FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024608254> ?p ?o ?g. }

• W2024608254 endingPage "117" @default.
• W2024608254 startingPage "105" @default.
• W2024608254 abstract "DFU (5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl)phenyl-2(5H)-furanone) was identified as a novel orally active and highly selective cyclo-oxygenase-2 (COX-2) inhibitor. In CHO cells stably transfected with human COX isozymes, DFU inhibited the arachidonic acid-dependent production of prostaglandin E2 (PGE2) with at least a 1,000 fold selectivity for COX-2 (IC50=41±14 nM) over COX-1 (IC50>50 μM). Indomethacin was a potent inhibitor of both COX-1 (IC50=18±3 nM) and COX-2 (IC50=26±6 nM) under the same assay conditions. The large increase in selectivity of DFU over indomethacin was also observed in COX-1 mediated production of thromboxane B2 (TXB2) by Ca2+ ionophore-challenged human platelets (IC50>50 μM and 4.1±1.7 nM, respectively). DFU caused a time-dependent inhibition of purified recombinant human COX-2 with a Ki value of 140±68 μM for the initial reversible binding to enzyme and a k2 value of 0.11±0.06 s−1 for the first order rate constant for formation of a tightly bound enzyme-inhibitor complex. Comparable values of 62±26 μM and 0.06±0.01 s−1, respectively, were obtained for indomethacin. The enzyme-inhibitor complex was found to have a 1 : 1 stoichiometry and to dissociate only very slowly (t1/2=1–3 h) with recovery of intact inhibitor and active enzyme. The time-dependent inhibition by DFU was decreased by co-incubation with arachidonic acid under non-turnover conditions, consistent with reversible competitive inhibition at the COX active site. Inhibition of purified recombinant human COX-1 by DFU was very weak and observed only at low concentrations of substrate (IC50=63±5 μM at 0.1 μM arachidonic acid). In contrast to COX-2, inhibition was time-independent and rapidly reversible. These data are consistent with a reversible competitive inhibition of COX-1. DFU inhibited lipopolysaccharide (LPS)-induced PGE2 production (COX-2) in a human whole blood assay with a potency (IC50=0.28±0.04 μM) similar to indomethacin (IC50=0.68±0.17 μM). In contrast, DFU was at least 500 times less potent (IC50>97 μM) than indomethacin at inhibiting coagulation-induced TXB2 production (COX-1) (IC50=0.19±0.02 μM). In a sensitive assay with U937 cell microsomes at a low arachidonic acid concentration (0.1 μM), DFU inhibited COX-1 with an IC50 value of 13±2 μM as compared to 20±1 nM for indomethacin. CGP 28238, etodolac and SC-58125 were about 10 times more potent inhibitors of COX-1 than DFU. The order of potency of various inhibitors was diclofenac>indomethacin∼naproxen>nimesulide∼ meloxicam∼piroxicam>NS-398∼SC-57666>SC-58125>CGP 28238∼etodolac>L-745,337>DFU. DFU inhibited dose-dependently both the carrageenan-induced rat paw oedema (ED50 of 1.1 mg kg−1 vs 2.0 mg kg−1 for indomethacin) and hyperalgesia (ED50 of 0.95 mg kg−1 vs 1.5 mg kg−1 for indomethacin). The compound was also effective at reversing LPS-induced pyrexia in rats (ED50=0.76 mg kg−1 vs 1.1 mg kg−1 for indomethacin). In a sensitive model in which 51Cr faecal excretion was used to assess the integrity of the gastrointestinal tract in rats, no significant effect was detected after oral administration of DFU (100 mg kg−1, b.i.d.) for 5 days, whereas chromium leakage was observed with lower doses of diclofenac (3 mg kg−1), meloxicam (3 mg kg−1) or etodolac (10–30 mg kg−1). A 5 day administration of DFU in squirrel monkeys (100 mg kg−1) did not affect chromium leakage in contrast to diclofenac (1 mg kg−1) or naproxen (5 mg kg−1). The results indicate that COX-1 inhibitory effects can be detected for all selective COX-2 inhibitors tested by use of a sensitive assay at low substrate concentration. The novel inhibitor DFU shows the lowest inhibitory potency against COX-1, a consistent high selectivity of inhibition of COX-2 over COX-1 (>300 fold) with enzyme, whole cell and whole blood assays, with no detectable loss of integrity of the gastrointestinal tract at doses >200 fold higher than efficacious doses in models of inflammation, pyresis and hyperalgesia. These results provide further evidence that prostanoids derived from COX-1 activity are not important in acute inflammatory responses and that a high therapeutic index of anti-inflammatory effect to gastropathy can be achieved with a selective COX-2 inhibitor. British Journal of Pharmacology (1997) 121, 105–117; doi:10.1038/sj.bjp.0701076" @default.
• W2024608254 created "2016-06-24" @default.
• W2024608254 creator A5004467990 @default.
• W2024608254 creator A5005486528 @default.
• W2024608254 creator A5007224785 @default.
• W2024608254 creator A5012641063 @default.
• W2024608254 creator A5014614899 @default.
• W2024608254 creator A5026259517 @default.
• W2024608254 creator A5026363362 @default.
• W2024608254 creator A5027177687 @default.
• W2024608254 creator A5031797767 @default.
• W2024608254 creator A5032940395 @default.
• W2024608254 creator A5033954493 @default.
• W2024608254 creator A5041061619 @default.
• W2024608254 creator A5041666909 @default.
• W2024608254 creator A5045507551 @default.
• W2024608254 creator A5052025426 @default.
• W2024608254 creator A5057342142 @default.
• W2024608254 creator A5058080747 @default.
• W2024608254 creator A5058120869 @default.
• W2024608254 creator A5063518304 @default.
• W2024608254 creator A5063566841 @default.
• W2024608254 creator A5065292923 @default.
• W2024608254 creator A5069441196 @default.
• W2024608254 creator A5071585890 @default.
• W2024608254 creator A5072740937 @default.
• W2024608254 creator A5074802359 @default.
• W2024608254 creator A5075106875 @default.
• W2024608254 creator A5075106990 @default.
• W2024608254 creator A5086549966 @default.
• W2024608254 creator A5091232423 @default.
• W2024608254 date "1997-05-01" @default.
• W2024608254 modified "2023-09-23" @default.
• W2024608254 title "Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor" @default.
• W2024608254 cites W1561747056 @default.
• W2024608254 cites W1972269110 @default.
• W2024608254 cites W1982273085 @default.
• W2024608254 cites W1993535520 @default.
• W2024608254 cites W1994442506 @default.
• W2024608254 cites W1994977169 @default.
• W2024608254 cites W1997364548 @default.
• W2024608254 cites W2001214229 @default.
• W2024608254 cites W2007504470 @default.
• W2024608254 cites W2018692599 @default.
• W2024608254 cites W2020092959 @default.
• W2024608254 cites W2024175 @default.
• W2024608254 cites W2024715019 @default.
• W2024608254 cites W2034404268 @default.
• W2024608254 cites W2034679499 @default.
• W2024608254 cites W2039358393 @default.
• W2024608254 cites W2039440412 @default.
• W2024608254 cites W2040040765 @default.
• W2024608254 cites W2041777500 @default.
• W2024608254 cites W2045654982 @default.
• W2024608254 cites W2049908664 @default.
• W2024608254 cites W2051009681 @default.
• W2024608254 cites W2053005216 @default.
• W2024608254 cites W2053966772 @default.
• W2024608254 cites W2055526753 @default.
• W2024608254 cites W2066074947 @default.
• W2024608254 cites W2070609164 @default.
• W2024608254 cites W2071214195 @default.
• W2024608254 cites W2076974145 @default.
• W2024608254 cites W2083748640 @default.
• W2024608254 cites W2085141220 @default.
• W2024608254 cites W2100417337 @default.
• W2024608254 cites W2103797244 @default.
• W2024608254 cites W2122355853 @default.
• W2024608254 cites W2146498309 @default.
• W2024608254 cites W2167809710 @default.
• W2024608254 cites W2951100061 @default.
• W2024608254 cites W2951287520 @default.
• W2024608254 cites W2951757604 @default.
• W2024608254 cites W3103908430 @default.
• W2024608254 cites W3189083562 @default.
• W2024608254 cites W4233149709 @default.
• W2024608254 doi "https://doi.org/10.1038/sj.bjp.0701076" @default.
• W2024608254 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1564640" @default.
• W2024608254 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9146894" @default.
• W2024608254 hasPublicationYear "1997" @default.
• W2024608254 type Work @default.
• W2024608254 sameAs 2024608254 @default.
• W2024608254 citedByCount "312" @default.
• W2024608254 countsByYear W20246082542012 @default.
• W2024608254 countsByYear W20246082542013 @default.
• W2024608254 countsByYear W20246082542014 @default.
• W2024608254 countsByYear W20246082542015 @default.
• W2024608254 countsByYear W20246082542016 @default.
• W2024608254 countsByYear W20246082542017 @default.
• W2024608254 countsByYear W20246082542018 @default.
• W2024608254 countsByYear W20246082542019 @default.
• W2024608254 countsByYear W20246082542020 @default.
• W2024608254 countsByYear W20246082542021 @default.
• W2024608254 countsByYear W20246082542022 @default.
• W2024608254 countsByYear W20246082542023 @default.
• W2024608254 crossrefType "journal-article" @default.
• W2024608254 hasAuthorship W2024608254A5004467990 @default.
• W2024608254 hasAuthorship W2024608254A5005486528 @default.

• next